Compare
Immuneering Corp vs Evolus, Inc. vs Evommune, Inc. vs Lifecore Biomedical, Inc.
| Latest fiscal year | Immuneering Corp IMRX | Evolus, Inc. EOLS | Evommune, Inc. EVMN | Lifecore Biomedical, Inc. LFCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-05-25 |
| Revenue | n/a | $297.18M | $13.00M | $128.87M |
| Revenue growth (YoY) | n/a | +11.6% | +85.7% | +0.5% |
| Gross margin | n/a | 66.3% | n/a | 31.3% |
| Operating margin | n/a | -11.0% | -623.6% | -13.4% |
| Net margin | n/a | -17.4% | -529.8% | -30.0% |
| Net income | -$56.02M | -$51.64M | -$68.87M | -$38.72M |
| EPS (Diluted) | -$1.27 | -$0.80 | -$11.22 | -$1.27 |
| Operating cash flow | -$45.34M | -$42.27M | -$76.44M | -$206.0K |
| Free cash flow | -$45.49M | -$45.71M | -$76.68M | -$13.62M |
| Cash & equivalents | $128.65M | $53.83M | $44.06M | $8.27M |
| Total assets | $231.99M | $225.87M | $224.95M | $239.34M |
| Total liabilities | $13.50M | $248.97M | $19.38M | $191.91M |
| Shareholders' equity | $218.48M | -$23.11M | $205.57M | $1.34M |
| Return on year-end equity | -25.6% | n/a | -33.5% | n/m |
| Shares outstanding | n/a | 65.01M | 31.52M | 37.03M |
Revenue, most recent five fiscal years
| Fiscal year | Immuneering Corp | Evolus, Inc. | Evommune, Inc. | Lifecore Biomedical, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $297.18M Ended 2025-12-31 | $13.00M Ended 2025-12-31 | $128.87M Ended 2025-05-25 |
| 1 year earlier | $317.0K Ended 2022-12-31 | $266.27M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $128.26M Ended 2024-05-26 |
| 2 years earlier | $2.08M Ended 2021-12-31 | $202.09M Ended 2023-12-31 | n/a | $103.27M Ended 2023-05-28 |
| 3 years earlier | $2.31M Ended 2020-12-31 | $148.62M Ended 2022-12-31 | n/a | $111.27M Ended 2022-05-29 |
| 4 years earlier | n/a | $99.67M Ended 2021-12-31 | n/a | $100.87M Ended 2021-05-30 |